New data reinforces AstraZeneca and Sanofi's nirsevimab as e

Nirsevimab is the first investigational immunisation designed to protect all infants across the RSV season with a single dose - News - PharmaTimes

Related Keywords

United Kingdom , Peric Sim , Astrazeneca , Uc Denver School Of Medicine , Mene Pangalos , Iusv , Nirsevimab ,